Swiss pharma giant Novartis (NVS) has agreed to license a novel capsid generated from Voyager Therapeutics, Inc’s (VYGR) capsid platform for use in a gene therapy program.Per Voyager, NVS will use this novel capsid for use in a gene therapy program against an undisclosed rare neurologic disease target.Shares of Novartis have risen 15.4% year to date compared with the industry’s growth of 27%.Image Source: Zacks Investment ResearchNovartis’ Deal With VYGRVYGR granted this capsid license to NVS per the terms ...